Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
  • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
  • A61L15/42—Use of materials characterised by their function or physical properties
  • A61L15/44—Medicaments
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
  • A01N25/34—Shaped forms, e.g. sheets, not provided for in any other sub-group of this main group
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N55/00—Biocides, pest repellants or attractants, or plant growth regulators, containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F13/00—Bandages or dressings; Absorbent pads
  • A61F13/01—Non-adhesive bandages or dressings
  • A61F13/01021—Non-adhesive bandages or dressings characterised by the structure of the dressing
  • A61F13/01029—Non-adhesive bandages or dressings characterised by the structure of the dressing made of multiple layers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
  • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
  • A61L15/42—Use of materials characterised by their function or physical properties
  • A61L15/425—Porous materials, e.g. foams or sponges
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
  • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
  • A61L31/146—Porous materials, e.g. foams or sponges
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
  • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
  • A61L31/16—Biologically active materials, e.g. therapeutic substances
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F13/00—Bandages or dressings; Absorbent pads
  • A61F2013/00089—Wound bandages
  • A61F2013/00238—Wound bandages characterised by way of knitting or weaving
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
  • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
  • A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
  • A61L2300/208—Quaternary ammonium compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
  • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
  • A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
  • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
  • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2400/00—Materials characterised by their function or physical properties
  • A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces

Definitions

• the present subject matter relates, in general, to a composite material and, particularly but not exclusively, to the composite material having a microbicidal activity.
• microbicidal agents on fibres and fabrics, that would effectively retard the growth of various microorganisms.
• sanitary wipes used for cleaning environmental, food contact surfaces, and personal and health care applications incorporate various microbicidal agents on its fabric to exhibit sanitizing and microbicidal properties.
• new drugs have now emerged for the treatment of drug resistant infections, the microorganisms that are treated with these new drugs are becoming increasingly drug resistant resulting in the creation of superbugs.
• pathogens By techniques that do not cause drug resistance in them.
• Fig. la illustrates cross-sectional view of a microbicidal composite material, in accordance with an embodiment of the present subject matter.
• FIG. 2 is an exemplary illustration of a microbicidal agent that is an integral part of the microbicidal composite material, in accordance with an embodiment of the present subject matter.
• Fig. 3a illustrates a pathogen being drawn towards a positively charged nitrogen, in accordance with an embodiment of the present subject matter.
• Fig. 3b illustrates rupturing a cell membrane of the pathogen, in accordance with an embodiment of the present subject matter.
• Fig. 4 illustrates a graphical representation of percentage killing of
• Pseudomonas aeruginosa P. aeruginosa
• P. aeruginosa Pseudomonas aeruginosa with the microbicidal composite material, in comparison with reference materials and an antibiotic drug, in accordance with an embodiment of the present subject matter.
• Fig. 5 illustrates a graphical representation of percentage killing of S. aureus with the microbicidal composite material, in comparison with reference materials and an antibiotic drug, in accordance with an embodiment of the present subject matter.
• Fig. 6b illustrates a graphical representation of the killing of S. aureus with the microbicidal composite material, after day 1 swab samples, in accordance with an embodiment of the present subject matter.
• Fig. 6c illustrates a graphical representation of the killing of P. aeruginosa with the microbicidal composite material, after day 1 swab samples, in accordance with an embodiment of the present subject matter.
• Fig. 7b illustrates a graphical representation of the killing of X aureus with the microbicidal composite material, after day 7 swab samples, in accordance with an embodiment of the present subject matter.
• Fig. 7c illustrates a graphical representation of the killing of P. aeruginosa with the microbicidal composite material, after day 7 swab samples, in accordance with an embodiment of the present subject matter.
• Fig. 8c illustrates a graphical representation of the killing of P. aeruginosa with the microbicidal composite material, after day 28 swab samples, in accordance with an embodiment of the present subject matter.
• FIG. 9a illustrates a pictorial illustration of bacteriological evaluation on excision wound healing in rats, in terms of wound contraction without infection with respect to S. aureus, P. aeruginosa after day 7, in accordance with an embodiment of the present subject matter.
• Fig. 9b illustrates a graphical representation of percentage contraction of the excision wound in quantitative terms without infection with respect to S. aureus, P. aeruginosa after day 7, in accordance with an embodiment of the present subject matter.
• Fig. 10b illustrates a graphical representation of percentage contraction of the excision wound in quantitative terms with infection with respect to S. aureus, after day 7, in accordance with an embodiment of the present subject matter.
• FIG. 11a illustrates a pictorial illustration of bacteriological evaluation on excision wound healing in rats, in terms of wound contraction with respect to P. aeruginosa, after day 7, in accordance with an embodiment of the present subject matter.
• Fig. 12b illustrates a graphical representation of percentage contraction of the excision wound in quantitative terms without infection with respect to S. aureus, P. aeruginosa after day 14, in accordance with an embodiment of the present subject matter.
• Fig. 14a illustrates a pictorial illustration of bacteriological evaluation on excision wound healing in rats, in terms of wound contraction with respect to P. aeruginosa, after day 14, in accordance with an embodiment of the present subject matter.
• Fig. 14b illustrates a graphical representation of percentage contraction of the excision wound in quantitative terms with infection with respect to P. aeruginosa, after day 14, in accordance with an embodiment of the present subject matter.
• Fig. 15b illustrates a graphical representation of percentage contraction of the excision wound in quantitative terms without infection with respect to S. aureus, P. aeruginosa after day 28, in accordance with an embodiment of the present subject matter.
• a three dimensional structure of a microbicidal composite material is herein described, in accordance with an implementation of the present subject matter.
• the described structure allows for efficient air circulation, thereby facilitating increased supply of oxygen to the wounded issues, and simultaneously restricts the entry of pathogens from the air entering into the wound, thereby alleviating the wound healing process.
• the described structure also allows for efficient wicking of the exudates from the surface of the wound by capillary action, thereby preventing the exudates on the wound to serve as a nutrient medium for multiplication of the pathogens.
• the described structure is also provided with increased number of surface moieties along layers of the composite material, thereby allowing for stronger and quantitatively larger binding of the microbicidal agent with the composite material.
• the surface moieties include functional groups that are available for the chemical bonding of the microbicidal agent.
• the chemical binding of the microbicidal agent to the surface moieties is via a covalent bonding. Such an interaction prevents eluting of the microbicidal agent into the wound thereby preventing the evolution of drug resistant microbes.
• each layer of the microbicidal composite material i.e., the first layer, the second layer, and the intermediate layer are associated with a first pre-defined stitch/thread density, second pre-defined stitch/thread density, and a third pre-defined stitch/thread density, respectively.
• the third pre-defined stitch/thread density is lesser than that of the first pre-defined stitch/thread density and the second pre-defined stitch/thread density.
• Such a differential stitch/thread density allows for wicking by capillary action on contact of at least one of the first layer and the second layer with a fluid.
• microbicidal composite material either in whole or in part of a wound dressing may be particularly helpful to promote healing of a wound, where the differential stitch/thread density allows for wicking exudates away from the wound, through one of the first layer and second layer on contact with the wound.
• This enhanced wicking feature ensures that, the exudates in the vicinity of the wound is effectively removed ensuring that it may no longer serve as a nutrient medium for the growth of pathogens, thereby facilitating wound healing.
• the exudate which is now held away from the wound is allowed to dry slowly by simple evaporation method promoted by the air circulation through the permeable microbicidal composite material.
• the pathogens present in the exudate are killed by the composite material thus ensuring that the spread of infections is curtailed.
• the wicking happens in such a way that the wound is left sufficiently moist for enabling the body to ensure healing without interfering in normal body healing mechanism.
• Such an interaction may prevent eluting of the microbicidal agent from the vicinity of the wound and thus provide for a continued larger concentration of the microbicidal agent, keeping a higher kill rate of pathogens on the wound, from the exudates and from the air coming in contact with the wound without interfering in normal wound healing, thereby promoting faster healing of the wound and also preventing the evolution of drug resistant microbes.
• the one or more material may be made by fibres, filaments, yarns and fabrics or combinations thereof.
• the material can include, but not limited to synthetic fibres, natural fibres, or combinations thereof.
• Synthetic fibres include, for example, acrylic, polyamide, polyolefin, polyaramide, polyurethane, poly acylonitriles, textured polyethylene terephthalate, polytriphenylene terephthalate, polybutylene terephthalate, polylactic acid, aramides, metaramides and combinations thereof.
• Polyamide includes, for example, nylon 6, nylon 6.6, and combinations thereof.
• the polyolefin's includes, for example, polypropylene, polyethylene, and combinations thereof.
• Polyaramide includes, for example, poly-p- phenyleneteraphthalamide, poly-m-phenyleneteraphthalamid, arid combinations thereof.
• Natural fibres include, for example, wool, cotton, flax, rayon, jute, linen and blends thereof.
• At least one layer in the three dimensional structure is composed of an elastomeric material, and wherein the elastomeric material includes at least one of a textured yarns, textured fibres, multi component yarns, multi component fibres, polyurethane and natural rubber to impart resilient property.
• a breathable film is applied to any one of the layer to cover it fully such that it is permeable for the gaseous exchange like vapour from the wound and air from atmosphere to the wound but limiting external water or chemicals soling the wound.
• at least one layer of the three dimensional structure may be composed of biopolymers, where the biopolymers include at least one selected from a group of poly lactic acid, poly glycolic acid and caprolactam.
• the pre-determined size may be controlled by adjusting stitch/thread density of the material in each layer of the three dimensional structure.
• each layer of the microbicidal composite material 100 i.e., the first layer 102, the second layer 104, and the intermediate layer 106 are associated with a first pre-defined stitch/thread density, second predefined stitch/thread density, , and a third pre-defined stitch/thread density.
• the stitch/thread density of these layers can be controlled by in the process of weaving, process of knitting, spacer knitting and non-woven process.
• the third pre-defined stitch/thread density is lesser than that of the first pre-defined stitch/thread density and the second pre-defined stitch/thread density.
• Such a differential stitch/thread density allows for wicking by capillary action on contact of at least one of the first layer 102 and the second layer 104 with a fluid.
• microbicidal composite The microbicidal composite
• the test item i.e., the microbicidal composite material exhibited a rapid inhibition of growth of both P. aeruginosa and S. aureus.
• the rate of kill versus P. aeruginosa is comparable to the reference standards (Fig 4), while the rate of kill vs. S. aureus was superior to one of the reference standards (Fig 5).
• Fig-4 and Fig- 5 show the inhibition of growth as percentage in the Y-axis compared to the untreated control group.
• the X-axis shows time reference in this study for Fig-4 and Fig-5.
• Fig-12a, Fig-12b, Fig-13a, Fig-13b, Fig-14a and Fig-14b illustrate the effect after day 14.
• Fig-15a, Fig-15b, Fig-16a, Fig-16b, Fig-17a and Fig- 17b illustrate the effect after day 28.
• Example 7 Test For In Vitro Cytotoxicity: Direct contact Method.
• Example 9 Test for intracutaneous reactivity study in New Zealand rabbits.
• microbicidal composite material 100 of the embodiments when used either as a whole or part in wound dressing, avoids contamination of wound by external pathogens.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Vascular Medicine (AREA)
• Heart & Thoracic Surgery (AREA)
• Hematology (AREA)
• Materials Engineering (AREA)
• Surgery (AREA)
• Dispersion Chemistry (AREA)
• Medicinal Chemistry (AREA)
• Biomedical Technology (AREA)
• Agronomy & Crop Science (AREA)
• Pest Control & Pesticides (AREA)
• Environmental Sciences (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Dentistry (AREA)
• Plant Pathology (AREA)
• Molecular Biology (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Toxicology (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Dermatology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Materials For Medical Uses (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=50896343

Family Applications (1)

Country Status (5)

Cited By (1)

Families Citing this family (2)

Citations (3)

Family Cites Families (10)

• 2014
  • 2014-05-15 JP JP2016513454A patent/JP2016522029A/ja active Pending
  • 2014-05-15 US US14/412,109 patent/US9566363B2/en active Active
  • 2014-05-15 CA CA2912124A patent/CA2912124A1/en not_active Abandoned
  • 2014-05-15 WO PCT/IB2014/000735 patent/WO2014184640A1/en not_active Ceased
  • 2014-05-15 EP EP14728623.1A patent/EP2981302B1/en active Active

Patent Citations (3)

Also Published As

Similar Documents

Legal Events